Company intelligence / Profile preview

Takgene

Iran

Ownership: Private
Employees: ~300
Development stage: Other

Overview

Takgene commercializes more than ten licensed probiotic products in Iran, including first-in-class products such as probiotic therapies targeting fatty liver disease, and is advancing two probiotic medicines for MS and Alzheimer's into the market after regulatory approval. It also produces products for respiratory diseases, including flu, and has shown strong pandemic response with its Bio Boost product.[1][2]

Therapeutic areas: EndocrinologyWomen's HealthGastroenterologyNeurologyPulmonology
Modalities: ProbioticLive biotherapeutic product therapy
Industry: Biotech

Beyond the preview

Go deeper on Takgene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Takgene.

Explore the full profile